Skip to main content

Table 3 Incidence and the risk ratios of COPD exacerbation (≥ 1 moderate or ≥ 1 severe) during 1-year follow-up according to the presence of chronic bronchitis and BMI categories in 1264 patients from the KOCOSS

From: Association of body mass index and COPD exacerbation among patients with chronic bronchitis

 

Cases/at risk

Person-years

Incidence rate (per 1000 person-years)

Crude IRR (95% CI)

Adjusteda IRR (95% CI)

Model 1

Model 2

Chronic bronchitis

 Non-CB

327/813

629

520

Reference

Reference

Reference

 CB

224/451

317

707

1.36 (1.14–1.62)

1.33 (1.12–1.59)

1.19 (0.97–1.44)

BMI (kg/m2)

 BMI ≥ 25

116/328

265

438

Reference

Reference

Reference

 BMI < 25

435/936

681

639

1.46 (1.19–1.79)

1.20 (0.97–1.48)

1.23 (0.97–1.56)

Chronic bronchitis and BMI (kg/m2)

 Non-CB and BMI ≥ 25

76/230

189

402

Reference

Reference

Reference

 Non-CB and BMI < 25

251/583

439

572

1.43 (1.10–1.84)

1.20 (0.89–1.55)

1.21 (0.89–1.62)

 CB and BMI ≥ 25

40/98

76

526

1.32 (0.90–1.94)

1.36 (0.91–2.00)

1.20 (0.77–1.88)

 CB and BMI < 25

184/353

241

763

1.90 (1.45–2.49)

1.58 (1.19–2.10)

1.41 (1.02–1.91)

  1. P values < 0.05 are presented in bold. BMI, body mass index; CB, chronic bronchitis; CCI, Charlson comorbidity index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; IRR, incidence rate ratios
  2. aModel 1 was adjusted for age, sex, educational level, smoking status (current smoker vs. ex-smoker vs. never-smoker) and post bronchodilator FEV1(continuous). Model 2 was further adjusted for ICS use (yes vs. no), CCI (continuous) and exacerbation in the previous year (yes vs. no) in addition to Model 1